News for April 2019

News Archive

Start Codon founded in Cambridge, UK, to deliver premier life science and healthcare business acceleration program

Start Codon, located in the heart of the Cambridge Cluster, aims to provide a much-needed world-class life science accelerator that offers significant funding and support to rapidly translate the most disruptive and innovative research into successful start-up companies. Start Codon’s founding investors include Cambridge Innovation Capital, Babraham Research Campus through Babraham Bioscience Technologies, Genentech, a member of the Roche Group, Dr Jonathan Milner and Dr Ian Tomlinson.

Medicines Discovery Catapult’s Virtual R&D Discovery Services platform announce twenty-two partnerships Medicines Discovery Catapult’s Virtual R&D Discovery Services platform announce twenty-two partnerships

Medicines Discovery Catapult today announces the launch of twenty-two partnerships with UK contract research organisations (CROs). The aim is to boost UK life sciences R&D and international competitiveness by channelling high quality projects through best-in-class service providers.

Maths made easier for scientists students who shun the subject wins award Maths made easier for scientists students who shun the subject wins award

Pharmacologist Dr Fraser Scott wins Royal Society of Chemistry award for his innovative approach to helping science students succeed in a maths-heavy module

The Current issue of “The view from here” is concerned with Partnerships and Alliances The Current issue of “The view from here” is concerned with Partnerships and Alliances

The topic of this month’s newsletter from Drug Discovery Today is “Partnerships and Alliances”.

Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

Invokana® (canagliflozin) is the only medicine in nearly 20 years and the first diabetes medicine to demonstrate significant reduction in risk of renal failure, dialysis or kidney transplantation and renal or cardiovascular (CV) death in this high-risk population